Elucidating Tumorigenesis Mechanisms and Assessing Immunotherapeutic Efficacy in Patient-Derived Medulloblastoma Organoid Models - PubMed
an hour ago
- #Immunotherapy
- #Organoids
- #Medulloblastoma
- Patient-derived medulloblastoma organoids (MBOs) were established to model tumor heterogeneity and investigate oncogenic mechanisms.
- MBOs retain histological, cellular, transcriptional, genomic, and epigenetic features of original tumors, confirmed by multi-omics analyses.
- They show strong infiltration capabilities in vitro and in vivo, useful for studying tumor microenvironment interactions.
- Photoreceptor-related pathways may be involved in Group 4 medulloblastoma pathogenesis, potentially influencing the tumor microenvironment.
- A prognostic nomogram was developed using specific gene expression levels (IMPG2, BNC2, PAPPA2, ITGBL1, UNC13C) to predict survival outcomes.
- Tumor-infiltrating lymphocytes (TILs) from patients exhibited cytotoxic activity against autologous MBOs and suppressed xenograft growth, indicating potential for TIL-based immunotherapy.
- MBOs serve as a valuable platform for studying tumorigenesis and evaluating therapeutic responses, aiding both biological research and clinical translation.